Nawel Bourayou

3.5k citations

25 papers · 2.4k indexed · 2 hit papers · h-index 9

Pulmonary and Respiratory Medicine top 1%
Oncology top 1%
Cancer Research top 2%
Genetics top 2%
Molecular Biology

Co-authors: Martin Frenzel Masakazu Toi Susana Barriga Joohyuk Sohn Angelo Di Leo Matthew P. Goetz Tammy Forrester In Hae Park
Topics: Advanced Breast Cancer Therapies (11 papers)HER2/EGFR in Cancer Research (6 papers)Cancer Immunotherapy and Biomarkers (6 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Genetics
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaCancer Research
Partner nations: United States France Japan

In The Last Decade

Nawel Bourayou

23 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Nawel Bourayou

Since Specialization

Citations

This map shows the geographic impact of Nawel Bourayou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nawel Bourayou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nawel Bourayou more than expected).

Fields of papers citing papers by Nawel Bourayou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nawel Bourayou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nawel Bourayou. The network helps show where Nawel Bourayou may publish in the future.

Co-authorship network of co-authors of Nawel Bourayou

This figure shows the co-authorship network connecting the top 25 collaborators of Nawel Bourayou. A scholar is included among the top collaborators of Nawel Bourayou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nawel Bourayou. Nawel Bourayou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1325MO Retifanlimab (Anti–PD-1 mAb) alone or in combination with Anti-LAG3 ± Anti-TIM3 mAbs In previously untreated, recurrent and/or metastatic (R/M) PD-L1+ HNSCC: A double-blind randomised controlled phase II trial 2025 ·Annals of Oncology ·(unknown),Amiran Matitashvili,(unknown),(unknown),(unknown),Hua Wang,Hsuan‐Cheng Huang,Francesco Perri,(unknown),(unknown),Amaury Daste,(unknown),(unknown),(unknown),Richard Schaub,Lin Cheng,Nawel Bourayou,Louis Viviers,(unknown)	0
2	First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors 2025 ·The Oncologist ·John D. Powderly,Martin Gutierrez,Ani Sarkis Balmanoukian,(unknown),Zhiwan Dong,Lulu Cheng,Xuejun Chen,John E. Janik,Nawel Bourayou,Omid Hamid	0
3	First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors 2025 ·The Oncologist ·Martin Gutierrez,Shou‐Ching Tang,John D. Powderly,Ani Sarkis Balmanoukian,(unknown),Zhiwan Dong,Lulu Cheng,Xiaohua Gong,John E. Janik,Nawel Bourayou,Omid Hamid	2
4	A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers. 2023 ·Journal of Clinical Oncology ·Martin Gutierrez,Ani Sarkis Balmanoukian,Anthony F. Shields,Melissa L. Johnson,Susanna V. Ulahannan,Minal Barve,(unknown),Feng Zhou,Nawel Bourayou,Omid Hamid	1
5	723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies 2022 ·Regular and Young Investigator Award Abstracts ·Sarina A. Piha‐Paul,Nawel Bourayou,Richard Schaub,(unknown),(unknown),Patrick A. Mayes,Tara C. Gangadhar	1
6	Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies 2018 ·Cancer Research ·Angelo Di Leo,(unknown),(unknown),Masakazu Toi,Tammy Forrester,Shivani Nanda,Andrew Koustenis,Nawel Bourayou,SR Johnston	2
7	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancerbreakdown → 2017 ·Journal of Clinical Oncology ·Matthew P. Goetz,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch–Shimon,Jens Huober,In Hae Park,Olivier Trédan,Shin‐Cheh Chen,Luís Manso,Orit Freedman,Georgina Garnica Jaliffe,Tammy Forrester,Martin Frenzel,Susana Barriga,Ian C. P. Smith,Nawel Bourayou,Angelo Di Leo	1125
8	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapybreakdown → 2017 ·Journal of Clinical Oncology ·George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,Eva‐Maria Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. P. Smith,Nawel Bourayou,Antonio Llombart‐Cussac	1103
9	MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer 2017 ·Annals of Oncology ·Angelo Di Leo,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch–Shimon,Jens Huober,(unknown),Olivier Trédan,(unknown),Luís Manso,Orit Freedman,Georgina Garnica Jaliffe,Tammy Forrester,Martin Frenzel,Susana Barriga,Ian C. P. Smith,Nawel Bourayou,Matthew P. Goetz	13
10	MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy 2017 ·Annals of Oncology ·Masakazu Toi,Chiun‐Sheng Huang,Y-H Im,Hiroji Iwata,Joohyuk Sohn,Hao‐Chien Wang,Norikazu Masuda,Yong Lin,Sachi Sakaguchi,Nawel Bourayou,Antonio Llombart‐Cussac,George W. Sledge	3
11	Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2 2017 ·Annals of Oncology ·(unknown),Hiroji Iwata,Petros Nikolinakos,J. Thaddeus Beck,Han Koh,(unknown),Yong Lin,Susana Barriga,(unknown),Nawel Bourayou,Antonio Llombart‐Cussac,George W. Sledge	1
12	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy 2017 ·Journal of Clinical Oncology ·George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,Eva‐Maria Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. P. Smith,Nawel Bourayou,Antonio Llombart‐Cussac	10
13	A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER). 2017 ·Journal of Clinical Oncology ·Sara M. Tolaney,Nawel Bourayou,Shom Goel,Anwar Hossain,Fabrice André	2
14	monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer 2016 ·Annals of Oncology ·Sara M. Tolaney,Nawel Bourayou,Shom Goel,Tammy Forrester,Fabrice André	2
15	Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer 2015 ·Lung Cancer ·Rohit Lal,Gunnar Hillerdal,Riyaz Shah,Barbara Crosse,Joyce Thompson,M. Nicolson,Anders Vikström,Vanessa Potter,Carla Visseren‐Grul,María Gabriela Lorenzo,Yulia Dyachkova,Nawel Bourayou,Yvonne Summers	21
16	MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC). 2015 ·Journal of Clinical Oncology ·Matthew P. Goetz,Masakazu Toi,Suzanne Klise,Martin Frenzel,Nawel Bourayou,Angelo Di Leo	12
17	Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial 2013 ·Lung Cancer ·Radj Gervais,G. Robinet,Christelle Clément-Duchêne,Fabrice Denis,Claude El Kouri,(unknown),Nadia Chouaki,Nawel Bourayou,Jean‐François Morère	27
18	Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer 2013 ·Lung Cancer ·F. Mornex,Karine Peignaux,T. Germain,(unknown),Nadia Chouaki,Nawel Bourayou,Jean‐Marc Tourani	6
19	Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design 2013 ·Health and Quality of Life Outcomes ·Rohit Lal,Nawel Bourayou,Gunnar Hillerdal,M. Nicolson,Anders Vikström,María Gabriela Lorenzo,Yulia Dyachkova,Susana Barriga,Carla Visseren‐Grul	10
20	[Chemotherapy-induced cardiotoxicity in the elderly]. 2008 ·PubMed ·(unknown),(unknown),Frédèric Selle,Joseph Gligorov,(unknown),(unknown),Nawel Bourayou,François Lokiec,Élisabeth Carola,Jean‐Pierre Lotz	1

About Nawel Bourayou

Nawel Bourayou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 25 papers that have together received 2.4k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). The work is most often cited by research in Oncology (1.9k citations), Pulmonary and Respiratory Medicine (2.1k citations) and Genetics (560 citations). Nawel Bourayou has collaborated with scholars based in United States, France and Japan. Frequent co-authors include Martin Frenzel, Masakazu Toi, Susana Barriga, Joohyuk Sohn, Angelo Di Leo, Matthew P. Goetz, Tammy Forrester, In Hae Park, Shin‐Cheh Chen and Olivier Trédan. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact